A Prospective Study for the Assessment of the Long-term Safety and Efficacy of Cx401 in Patients Taking Part in the FATT-1 Trial
Latest Information Update: 06 Nov 2021
At a glance
- Drugs CX 401 (Primary)
- Indications Rectal fistula
- Focus Adverse reactions; Registrational
- Sponsors Cellerix; TiGenix
- 18 Sep 2014 New trial record